Correlation between the expression of S100A4 and the efficacy of TAC neoadjuvant chemotherapy in breast cancer

Li,Wen‑Lei; Zhang,Yang; Liu,Bao‑Guo; Du,Qian; Zhou,Chang‑Xin; Tian,Xing‑Song

doi:10.3892/etm.2015.2743

Correlation between the expression of S100A4 and the efficacy of TAC neoadjuvant chemotherapy in breast cancer

Authors:
- Wen‑Lei Li
- Yang Zhang
- Bao‑Guo Liu
- Qian Du
- Chang‑Xin Zhou
- Xing‑Song Tian
View Affiliations

Affiliations: Department of Breast and Thyroid Surgery, Shandong Provincial Hospital, Shandong University, Jinan, Shandong 250021, P.R. China, Department of Breast and Thyroid Surgery, People's Hospital of Liaocheng, Liaocheng, Shandong 252000, P.R. China, Department of Pediatrics, People's Hospital of Liaocheng, Liaocheng, Shandong 252000, P.R. China
Published online on: September 11, 2015 https://doi.org/10.3892/etm.2015.2743
Pages: 1983-1989

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the correlation between the expression of S100A4 and the efficacy of neoadjuvant chemotherapy in breast cancer. A total of 65 patients with invasive breast cancer were treated with neoadjuvant chemotherapy using the TAC regimen. The expression of S100A4 was detected by an immunohistochemical two‑step method prior to treatment, after 2 cycles of chemotherapy and after 4 cycles of chemotherapy. Pathological evaluations of the chemotherapy were performed using the Miller and Payne (MP) grading system and their correlation with the changes of S100A4 expression during and after the treatment were explored. Between pre‑neoadjuvant chemotherapy and 4 cycles post‑chemotherapy, there was a significant difference in the expression of S100A4 (P<0.05); S100A4 expression was associated with neoadjuvant chemotherapy. However, between pre‑neoadjuvant chemotherapy and 2 cycles post‑chemotherapy, there was no significant difference in the expression of S100A4 (P>0.05). The intensity and changes of S100A4 expression were positively correlated with the efficacy of neoadjuvant chemotherapy (r=0.259, P<0.05). When patients with an MP grade of I or II following the second cycle of neoadjuvant chemotherapy were continually treated with the original chemotherapy for another 2 cycles, the desired effect was generally not achieved. S100A4 may be used as a predictor of the efficacy of neoadjuvant chemotherapy in breast cancer, guiding the formulation of individualized programs to improve the effectiveness of the treatment. For patients with an MP grade level of I or II after 2 cycles of neoadjuvant chemotherapy, the use of alternative chemotherapy regimens should be considered.

View Figures

View References

1	Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, et al: Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 26:778–785. 2008. View Article : Google Scholar : PubMed/NCBI
2	Schmidt-Hansen B, Klingelhöfer J, Grum-Schwensen B, Christensen A, Andresen S, Kruse C, Hansen T, Ambartsumian N, Lukanidin E and Grigorian M: Functional significance of metastasis-inducing S100A4(Mts1) in tumor-stroma interplay. J Biol Chem. 279:24498–24504. 2004. View Article : Google Scholar : PubMed/NCBI
3	Garrett SC, Varney KM, Weber DJ and Bresnick AR: S100A4, a mediator of metastasis. J Biol Chem. 281:677–680. 2006. View Article : Google Scholar : PubMed/NCBI
4	Emberley ED, Murphy LC and Watson PH: S100 proteins and their influence on pro-survival pathways in cancer. Biochem Cell Biol. 82:508–515. 2004. View Article : Google Scholar : PubMed/NCBI
5	Lee WY, Su WC, Lin PW, Guo HR, Chang TW and Chen HH: Expression of S100A4 and Met: Potential predictors for metastasis and survival in early-stage breast cancer. Oncology. 66:429–438. 2004. View Article : Google Scholar : PubMed/NCBI
6	Rudland PS, Platt-Higgins A, Renshaw C, West CR, Winstanley JH, Robertson L and Barraclough R: Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. Cancer Res. 60:1595–1603. 2000.PubMed/NCBI
7	Kikuchi N, Horiuchi A, Osada R, Imai T, Wang C, Chen X and Konishi I: Nuclear expression of S100A4 is associated with aggressive behavior of epithelial ovarian carcinoma: An important autocrine/paracrine factor in tumor progression. Cancer Sci. 97:1061–1069. 2006. View Article : Google Scholar : PubMed/NCBI
8	Kim JH, Kim CN, Kim SY, Lee JS, Cho D, Kim JW and Yoon SY: Enhanced S100A4 protein expression is clinic pathologically significant to metastatic potential and p53 dysfunction in colorectal cancer. Oncol Rep. 22:41–47. 2009. View Article : Google Scholar : PubMed/NCBI
9	Agerbaek M, Alsner J, Marcussen N, Lundbeck F and Von der Maase H: Focal S100A4 protein expression is an independent predictor of development of metastatic disease in cystectomized bladder cancer patients. Eur Urol. 50:777–785. 2006. View Article : Google Scholar : PubMed/NCBI
10	Andersen K, Nesland JM, Holm R, Flørenes VA, Fodstad Ø and Maelandsmo GM: Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol. 17:990–997. 2004. View Article : Google Scholar : PubMed/NCBI
11	Taylor S, Herrington S, Prime W, Rudland PS and Barraclough R: S100A4(p9Ka) protein in colon carcinoma and liver metastases: Association with carcinoma cells and T-lymphocytes. Br J Cancer. 86:409–416. 2002. View Article : Google Scholar : PubMed/NCBI
12	Komatsu K, Murata K, Kameyama M, Ayaki M, Mukai M, Ishiguro S, Miyoshi J, Tatsuta M, Inoue M and Nakamura H: Expression of S100A6 and S100A4 in matched samples of human colorectal mucosa, primary colorectal adenocarcinomas and liver metastases. Oncology. 63:192–200. 2002. View Article : Google Scholar : PubMed/NCBI
13	Kriajevska M, Tarabykina S, Bronstein I, Maitland N, Lomonosov M, Hansen K, Georgiev G and Lukanidin E: Metastasis-associated Mts1(S100A4) protein modulates protein kinase C phosphorylation of the heavy chain of nonmuscle myosin. J Biol Chem. 273:9852–9856. 1998. View Article : Google Scholar : PubMed/NCBI
14	Chen ZW and Liao ML: RECIST criteria used in evaluating the efficacy of cancer therapy. Zhong Guo Ai Zheng. 10:6–8. 2004.(In Chinese).
15	Corben AD, Abi-Raad R, Popa I, Teo CH, Macklin EA, Koerner FC, Taghian AG and Brachtel EF: Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: A comparison between classifications and their practical application. Arch Pathol Lab Med. 137:1074–1082. 2013. View Article : Google Scholar : PubMed/NCBI
16	Liu G and Wang YS: Progress of breast-conserving surgery after neoadjuvant chemotherapy for breast cancer. Zhongguo Pu Wai Ji Chu Yu Lin Chuang Za Zhi. 17:1249–1252. 2010.(In Chinese).
17	Ring AE, Smith IE, Ashley S, Fulford LG and Lakhani SR: Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 91:2012–2017. 2004. View Article : Google Scholar : PubMed/NCBI
18	Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E and Wolmark N: Pathbiology of preoperative chemotherapy: Findings from the national surgical adjuvant breast and bowel (NSABP) protocol B-18. Cancer. 95:681–695. 2002. View Article : Google Scholar : PubMed/NCBI
19	Zhang J, Zhang DL, Jiao XL and Dong Q: S100A4 regulates migration and invasion in hepatocellular carcinoma HepG2 cells via NF-κB-dependent MMP-9 signal. Eur Rev Med Pharmacol Sci. 17:2372–2382. 2013.PubMed/NCBI
20	Helfman DM, Kim EJ, Lukanidin E and Grigorian M: The metastasis associated protein S100A4: Role in tumor progression and metastasis. Br J Cancer. 92:1955–1958. 2005. View Article : Google Scholar : PubMed/NCBI
21	Albertazzi E, Cajone F, Leone BE, Naguib RN, Lakshmi MS and Sherbet GV: Expression of metastasis-associated genes h-mts1 (S100A4) and nm23 in carcinoma of breast is related to disease progression. DNA Cell Biol. 17:335–342. 1998. View Article : Google Scholar : PubMed/NCBI
22	Wang XS, Lin SS, Wang GY, Zou DL, Chen HS and You Q: Correlation between S100A4 and E-Cad protein expression and invasion, metastasis and prognosis of colorectal cancer. Zhongguo Zhong Liu Lin Chuang. 36:690–693. 2009.(In Chinese).
23	Jin L, Shen Q, Ding S, Jiang W, Jiang L and Zhu X: Immunohistochemical expression of Annexin A2 and S100A proteins in patients with bulky stage IB-IIA cervical cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 126:140–146. 2012. View Article : Google Scholar : PubMed/NCBI
24	Ambartsumian N, Klingelhöfer J, Grigorian M, Christensen C, Kriajevska M, Tulchinsky E, Georgiev G, Berezin V, Bock E, Rygaard J, et al: The metastasis-associated Mts1 (S100A4) protein could act as an angiogenic factor. Oncogene. 20:4685–4695. 2001. View Article : Google Scholar : PubMed/NCBI
25	Wang Q, Yu MH, Wang G and Wang MH: Expression and clinical significance of DLL4 and S100A4 in different molecular subtypes of breast carcinoma. Zhongguo Pu Wai Ji Chu Yu Lin Chuang Za Zhi. 19:957–961. 2012.(In Chinese).
26	Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC and O'Connell P: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 362:362–369. 2003. View Article : Google Scholar : PubMed/NCBI
27	Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, et al: Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin and cyclpophosphamide in breast cancer. J Clin Oncol. 24:4236–4244. 2006. View Article : Google Scholar : PubMed/NCBI
28	Li SJ, Han B, Fu T, Shi AP, Wu D, Liu GJ and Fan ZM: The relationship between ER, PR and the expression of HER-2 and breast cancer neoadjuvant chemotherapy reaction. Zhong Guo Lao Nian Xue Za Zhi. 29:474–476. 2009.(In Chinese).
29	MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I and Coindre JM: Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer. 74:1458–1465. 1996. View Article : Google Scholar : PubMed/NCBI
30	Zhou QH, Wu Y, Cai ZR and Zhu JX: Influence of neoadjuvant chemotherapy on ER, PR, C-erbB-2, Ki-67 expressions of breast cancer patients. Zhong Guo Ai Zheng Za Zhi. 18:139–141. 2008.(In Chinese).
31	Zhao YC, Li Y, Zhu YY and Luo CY: Significance of expression changes of ER, PR, p53 and Bcl-2 induced by neoadjuvant chemotherapy (NAC) in breast cancer. Xian Dai Zhong Liu Yi Xue. 19:2017–2020. 2011.(In Chinese).